T1	Participants 51 84	patients with atrial fibrillation
T2	Participants 902 1023	4628 patients with a history of paroxysmal/persistent AF and additional risk factors, treated with placebo or dronedarone
T3	Participants 1218 1327	About half of the CV hospitalizations were AF-related, with a median duration of hospital stay of four nights
